Welcome to our dedicated page for Palisade Bio SEC filings (Ticker: PALI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Palisade Bio, Inc. (Nasdaq: PALI) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-assisted summaries to help interpret complex documents. As a clinical-stage biopharmaceutical company focused on autoimmune, inflammatory, and fibrotic diseases, Palisade Bio uses SEC filings to describe its development of once-daily, oral PDE4 inhibitor prodrugs, capital-raising activities, and corporate governance matters.
Through registration statements such as Form S‑1, investors can review detailed information about Palisade Bio’s business, risk factors, and public offerings of common stock and pre-funded warrants. These documents outline how the company intends to finance its clinical programs, including the advancement of its lead candidate PALI-2108 for ulcerative colitis and fibrostenotic Crohn’s disease. AI tools on this page can highlight key sections, such as use of proceeds, dilution, and summary business descriptions.
Current reports on Form 8‑K provide timely updates on material events. Recent 8‑Ks discuss topics such as Nasdaq minimum bid price compliance, the adoption and later termination of a Phantom Unit Plan for executives and directors, outcomes of annual meetings of stockholders, and the approval of a reverse stock split authorization within a specified ratio range. These filings also cover voting results, equity-based compensation arrangements, and other corporate actions relevant to shareholders.
Proxy statements on Schedule 14A offer further detail on director elections, auditor ratification, capital structure proposals, and special meeting agendas, including warrant-related share issuance approvals. On Stock Titan, AI-powered analysis can help users quickly identify the portions of these filings that address governance changes, executive arrangements, and share authorization requests. Together, the real-time feed of SEC documents and AI summaries enables a structured view of how Palisade Bio manages its capital structure, listing status, and development priorities for its gut-targeted PDE4 inhibitor prodrug platform.
Palisade Bio's preliminary proxy requests shareholder votes on three principal proposals: elect three directors for terms ending at the 2026 annual meeting, ratify Baker Tilly US, LLP as the independent registered public accounting firm for fiscal 2025, and approve an amendment authorizing the Board to implement a reverse stock split at a ratio between 1-for-5 and 1-for-50 to be effected on or before December 31, 2025. The document explains voting methods for an online-only annual meeting and describes factors the Board will consider in setting a split ratio, including trading price, liquidity, authorized shares and potential impacts on market capitalization and Nasdaq continued listing. Proxy voting procedures, potential odd-lot effects post-split, executive compensation disclosures and recent financing transactions with institutional investors (including Armistice Capital) and exercise-price adjustments for previously issued warrants are included.
Palisade Bio, Inc. filed an 8-K reporting executive change-in-control payment triggers tied to a Liquidity Change in Control and post-change termination events. The filing states that if an executive is terminated without cause or for good reason within 12 months following a Liquidity Change in Control, a severance payment becomes payable in a lump sum within 60 days. The same 60-day lump-sum timing is repeated for payments tied to the 7th anniversary of the Date of Grant and for amounts explicitly linked to the Liquidity Change in Control. The document is signed by J.D. Finley, Chief Executive Officer, and discloses timing and trigger mechanics but does not state specific payment amounts.
Palisade Bio director Donald Allen received a grant of 64,400 phantom units on 09/04/2025. Each phantom unit represents the economic equivalent of one share of Palisade Bio common stock. The award vests in three equal annual installments beginning August 5, 2026, provided the reporting person remains in continuous service through each vesting date. Vested phantom units will be settled solely in cash based on the fair market value of an equal number of shares upon termination of service, a liquidity change in control, or the seventh anniversary of the grant. The reporting person’s ownership after the grant is 64,400 common stock equivalents, held directly.
Palisaade Bio insider grant: The filing shows that John David Finley, a director and officer (listed as CEO, CFO), was granted 323,400 Phantom Units on 09/04/2025. Each Phantom Unit equals the economic value of one share of common stock and the award vests in 12 equal quarterly installments beginning November 5, 2025, subject to the reporting persons continuous service through each vesting date. Vested Phantom Units will be settled solely in cash based on the fair market value of an equal number of shares upon the earliest of termination by the issuer without cause, a liquidity change in control, or the 7th anniversary of the grant date, per the issuers Phantom Unit Plan. The Form 4 was signed by an attorney-in-fact on 09/05/2025.
Wei Binxian, a director of Palisade Bio, Inc. (PALI), was granted 18,800 phantom units on 09/04/2025. Each phantom unit mirrors the economic value of one share of common stock and the grant is recorded as 18,800 units with a $0 exercise price. The phantom units vest in three equal annual installments beginning August 5, 2026, subject to the reporting persons continuous service through each vesting date. Vested units will be settled solely in cash based on the fair market value of an equal number of shares upon termination of service, a defined change in control, or the seventh anniversary of the grant date. The Form 4 was signed by an attorney-in-fact on 09/05/2025.
Palisade Bio insider grant: Jones Mitchell Lawrence, listed as an officer serving as Chief Medical Officer, was granted 289,000 Phantom Units on 09/04/2025. Each Phantom Unit equals one share of common stock and the award was granted at $0 per unit. The Phantom Units vest in 12 equal quarterly installments beginning November 5, 2025, contingent on continuous service, and vested units are payable solely in cash based on the fair market value of the underlying shares upon specified settlement events including termination by the issuer without Cause, a liquidity change in control, or the seventh anniversary of the grant. The filing reports 289,000 shares beneficially owned following the transaction and is signed by an attorney-in-fact on 09/05/2025.
Emil Chuang, a director of Palisade Bio, Inc. (PALI), was granted 18,800 phantom units on 09/04/2025. Each phantom unit equals one share of common stock and the units were granted at $0 per unit. The units vest in three equal annual installments beginning August 5, 2026, subject to continued service.
Vested phantom units will be settled solely in cash based on the fair market value of the equivalent number of shares upon termination of service, a defined liquidity change in control, or the seventh anniversary of the grant. The Form 4 reports 18,800 shares beneficially owned following the transaction and is signed by attorney-in-fact Ryker Willie on 09/05/2025.
Fragment from Palisade Bio, Inc.'s definitive proxy (DEF 14A) lists beneficial ownership counts for named individuals. The excerpt shows Donald Williams with 7,178 shares, Binxian Wei with 4,115 shares, J.D. Finley with 34,351 shares, Mitchell Jones, M.D., Ph.D., with 13,307 shares, and a total line showing 58,951 (context truncated). The table fragment also indicates that an asterisk denotes holdings that represent less than one percent. Several entries (Emil Chuang and others) show a dash or are otherwise not quantified in this excerpt. This content is a partial ownership table and does not provide broader narrative, percentages relative to outstanding shares, or transaction details.
Palisade Bio, Inc. has filed an S-3 shelf registration that lists a block of 988,872 shares, shown as 10.24% relative to the disclosed share counts. The filing shows individual holdings including Nicholas Stergis: 248,687 shares (2.65%) and Ladenburg Thalmann & Co. Inc.: 229,952 shares (2.46%), along with smaller insider holdings for David Coherd (35,125), Andrew Moorefield (17,563), and Dan Daley (2,500).
The document also discloses estimated offering expenses: Legal Fees $20,000, Accountants' Fees $17,500, and a total of $49,000. The filing is signed on August 15, 2025.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 478,945 shares of Palisade Bio, Inc. The filing states the Reporting Persons share voting and dispositive power over these shares, representing 4.99% of the outstanding common stock. Armistice Capital is disclosed as the investment manager of the direct holder, the Master Fund, and Steven Boyd is identified as the managing member of Armistice Capital. The Master Fund is described as the direct holder but disclaims beneficial ownership due to its investment management agreement with Armistice Capital. The filing affirms the holdings were acquired in the ordinary course of business and not for the purpose of changing control.